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Summary. Objectives: Clinical trials have demonstrated that
oral conjugated equine estrogen (CEE) therapy with or
without medroxyprogesterone (MPA) increases venous
thrombotic risk but this safety issue has not been investi-
gated for other oral estrogens. Based on observational study
findings that esterified estrogen (EE) was not associated with
venous thrombotic risk whereas CEE was, we hypothesized
that CEE users would be more resistant to activated protein
C (APC), a prothrombotic phenotype, than EE users.
Methods: We conducted an observational, cross-sectional
study of postmenopausal women 30–89 years old who were
controls in a case–control study of venous thrombosis. Use
of CEE, EE, and MPA at the time of phlebotomy was
determined using computerized pharmacy records. APC
resistance was measured in plasma by the endogenous
thrombin potential normalized APC sensitivity ratio. Adjus-
ted mean APC resistance values were compared across
estrogen type and CEE:EE ratios are presented. Results:
There were 119 CEE and 92 EE users at the time of
phlebotomy. Compared with EE users, CEE users had APC
resistance measures that were 52% higher (1.52; 95%
confidence intervals: 1.07–2.17) in adjusted analyses.
Restricting to modal dose users (0.625 mg) and stratifying
by MPA use did not materially change associations.
Conclusions: CEE use was associated with higher levels of
APC resistance when compared with EE use in post-
menopausal women. These findings might provide an
explanation for the higher risk of venous thromboembolism
previously observed with CEE compared with EE use and,
if replicated, may have safety implications for women when
choosing an estrogen for symptom relief.
Keywords: activated protein C resistance, estrogen, postmeno-
pausal, progestin.
Introduction
Clinical trials have repeatedly demonstrated that oral conju-
gated equine estrogen (CEE) therapywith or withoutmedroxy-
progesterone (MPA) increases venous thrombotic risk, often
within the first year of treatment [1–3]. No large clinical trial
has evaluated this safety issue for other oral estrogen or
progestin compounds that continue to be used to treat
menopause-related vasomotor symptoms in peri- and post-
menopausal women.
In our population-based, case–control study, women who
used oral CEE had an 80% higher risk of venous thrombosis
than women who used oral esterified estrogen (EE) [4], a
synthetic estrogen derived from yams and soybeans. We also
observed that among estrogen users, MPA use compared with
non-use increased risk by 60%. Based on these findings, we
hypothesized that controls using oral CEE would have a more
prothrombotic hemostatic profile than controls using oral EE
and that among controls using either estrogen,MPAuse would
be associated with a more prothrombotic profile compared
with non-use. Our primary assessment of a prothrombotic
profile was increased resistance to activated protein C (APC), a
global measure of anticoagulation that predicts venous
thrombotic risk [5–10]. We also assessed five other parameters
[factor (F) VII, D-dimer, antithrombin (AT), and total and free
protein S] to characterize the hemostatic profile of hormone
users [11–13].
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Methods
Design and setting
This observational, cross-sectional study was conducted within
Group Health Cooperative (GHC), a health maintenance
organization in western Washington State, USA.
Subjects
Subjects were postmenopausal women 30–89 years of age who
were identified and recruited from January 1, 1995 to
December 31, 2001 as control subjects in an on-going case–
control study of hormone therapy and risk of venous
thrombosis [4]. All subjects provided signed informed consent.
Measures
All subjects had been assigned an index date: a computer-
generated randomdatewithin the same year for which they had
been sampled as controls.Medical history and clinical informa-
tion through the index date, such as menopausal and hysterec-
tomy status, height, and weight, were obtained from GHC
ambulatorymedical record; self-reported health status and race
were collected by telephone interview. Controls who partici-
pated inthe interviewwerealso invitedtodonateabloodsample.
Phlebotomy Venous blood was drawn from the antecubital
vein and the first 4.5 mL of blood was collected into a tube of
3.8% sodium citrate. Samples were transferred to a specimen-
processing center where citrated samples were centrifuged at
4 C for 10 min at 1300 · g and stored at )70 C. Samples
that were processed and frozen outside a 4-h window were
excluded from analyses.
Hormone use Useofhormones at the timeofphlebotomywas
determined using the GHC computerized pharmacy database
that contains information on drug name, prescription fill date,
medication strength and quantity prescribed, and dosing
instructions or the days supply of medication. More than
95%ofGHCmembers in this agegroupfill all or almost all their
prescriptions through GHC pharmacies [14].
A woman was considered a current user of a hormone if she
received enough medication with her last prescription to last
until the phlebotomy date and if she also had accumulated at
least 90 days of use immediately prior to the phlebotomy date.
The type of estrogen a woman was using at phlebotomy was
determined primarily by when blood was drawn. Women who
had draws prior toOctober 1999were primarily EE users as EE
was the standard postmenopausal estrogen therapy dispensed
at GHC pharmacies in this time period. GHC pharmacies
switched the standard estrogen therapy for current and new
users from EE to CEE in October 1999 so women with blood
draws after the switch date were primarily CEE users.
Formulary switches such as these occur in health maintenance
organization settings when medications are thought to be
therapeutically interchangeable [15–17]. Progestin use was
primarily determined by hysterectomy status.
Oral estrogens were classified into two groups: CEE, such as
Premarin (Wyeth Pharmaceuticals Inc., Philadelphia, PA,
USA); and EE, such as Estratab (Solvay Pharmaceuticals,
Marietta, GA, USA) and Menest (Monarch Pharmaceuti-
cals, Inc., Bristol, TN, USA). The progestin prescribed was
almost exclusively MPA and was dispensed as a separate pill
from estrogen in virtually all subjects. Women who used non-
oral estrogens and oral hormones other than CEE, EE, and
MPA at the time of the blood draw were excluded from the
study. Any subject who received a prescription for anticoagu-
lant or antiplatelet medications or vitamin K in the 180 days
before phlebotomy was excluded.
Laboratory assays Citrated plasma was shipped at )70 C
from Seattle, WA, USA, to Leiden, the Netherlands. Plasma
was thawed and centrifuged at 14 000 · g for 5 min and half
the content was immediately used to measure APC resistance
using the endogenous thrombin potential (ETP) normalized
APC sensitivity ratio (nAPCsr) assay [6,18]. The unused
content was refrozen at )70 C for the remaining five assays.
The normalized APC sensitivity ratio is the ratio of the amount
of thrombin generated in the absence of APC and the quantity
generated in the presence of APC in plasma free of fibrinogen
and then normalized to the same ratio derived from the plasma
of normals [7]. All laboratory normals had APC measured in
3.2% citrated plasma (new laboratory standard) whereas all
subjects had APC measured in 3.8% concentration so APC
sensitivity ratios are less than 1. Coagulation FVII activity was
determined by clotting time (STA Factor VII; Diagnostica
Stago, Asnie`res, France); D-dimer was measured by enzyme
immunoassay (Asserachrom D-Dimer; Diagnostica Stago);
AT activity was measured by thrombin neutralization (STA
Antithrombin III; Diagnostica Stago); and total and free
protein S antigen levels were measured separately (Liatest
Protein S and Liatest Free Protein S; Diagnostica Stago). All
tests were done in duplicates. Lab technicians were blinded to
the type of hormone therapy used by the subjects. The inter-
assay coefficient of variation for ETP-nAPCsr, FVII, D-dimer,
AT, and protein S total and free were 6.4%, 7.0%, 4.7%, 3.2%,
3.6%, and 5.0%, respectively. High values for ETP-nACPsr,
FVII and D-dimer and low values for AT and total and free
protein S indicated a more prothrombotic profile. Hemostatic
factor levels were measured in 109 control women who were
not using estrogen and who are not included in these analyses;
median levels were 0.22 for nAPCsr, 132% for FVII,
578 ng mL)1 for D-dimer, 111% for AT, 96% for free
protein S and 123% for total protein S.
Carriers of the FV 1691A (Leiden) variant were identified
using standard methods [19].
Analyses We compared levels of hemostatic measures across
hormone regimens using multivariate linear regression with
adjustment for age, race (white vs. other), body mass index
[weight (kg) height (m))2], self-reported health (good, very
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good, or excellent vs. poor or fair), hysterectomy status, MPA
use, estrogen dose [indicator variables for low dose
(< 0.625 mg day)1) and high dose (> 0.625 mg day)1)], and
recency of starting current therapy (less than 2 years vs. 2 or
more years). All measures were log transformed and differences
in hemostatic measure levels are reported as a CEE : EE ratio
or a MPA : no-MPA ratio of the adjusted medians with 95%
confidence intervals (CI). In secondary analyses, we examined
associations restricted to users of the modal estrogen dose
(0.625 mg day)1) and among subgroups defined by MPA use,
FV Leiden (FVL) carriership, and recency of starting hormone
therapy.
Results
We identified 71 women using CEE alone, 45 using CEE +
MPA, 45 using EE alone, and 47 using EE + MPAat the time
of phlebotomy and who met all eligibility criteria. Table 1
presents characteristics of the 208 subjects in the study and
hormone duration and dose information. Table 2 presents
unadjustedmedian values and interquartile range values for the
six hemostatic measures according to estrogen type and MPA
use. In descriptive analyses, median values of nAPCsr andFVII
activity appeared higher andmedian values ofATactivity, total
and free protein S lower in CEE users than in EE users. In
general, median values did not appear to vary by MPA use.
Table 3 presents unadjusted median values for the six
hemostatic measures according to estrogen type. Compared
with EE users, CEE users had APC resistance measures that
were 52% higher after adjusting for age, race, and body mass
index (CEE:EE ratio: 1.52; 95% CI: 1.07–2.17; P ¼ 0.020).
Further adjustment for hysterectomy status, MPA use, dose,
and recency of starting did not materially change estimates
(ratio: 1.49; 95%CI: 1.00–2.20; P ¼ 0.049). For the remaining
five parameters, the hemostatic profile was more prothrom-
botic among CEE users than EE users (higher levels of FVII
andD-dimer, and lower levels of AT, and free and total protein
S) but not all differences reached statistical significance.
We further investigated the CEE and EE comparison by
investigating subgroups. The FVL mutation was strongly
associated with increased resistance to APC: mean APC
resistance measures were 0.77 and 2.91 among those without
and with the mutation, respectively. Among women without
the mutation, CEE users remained more resistant to APC than
EE users (ratio: 1.54; 95% CI: 1.07–2.23; P ¼ 0.021); among
women with the mutation, the association was similar (ratio:
1.30; 95% CI: 0.70, 2.41; P ¼ 0.362). There was no statistical
evidence of an interaction between estrogen type and the
Table 1 Subject characteristics by hormone use
Characteristic
Hormone therapy
CEE alone
(n ¼ 71)
CEE + MPA
(n ¼ 45)
EE alone
(n ¼ 45)
EE + MPA
(n ¼ 47)
Mean age, years (SD) 68.3 (10.0) 65.4 (10.2) 66.6 (9.7) 63.3 (9.4)
White (%) 92 89 96 96
Good/excellent health (%) 82 89 86 91
Body mass index (SD) 29.1 (6.3) 26.9 (5.4) 27.5 (6.3) 30.4 (9.3)
Hysterectomy (%) 92 2 87 0
Perimenopausal (%) 1 9 0 13
Factor V Leiden carrier (%) 8 9 9 9
Starting estrogen use within 2 years (%) 61 58 24 34
Estrogen daily dose (%)
<0.625 mg 13 4 13 15
0.625 mg 69 89 82 85
>0.625 mg 18 7 4 0
EE, esterified estrogen; CEE, conjugated equine estrogen; MPA, medroxyprogesterone; SD, standard deviation.
Table 2 Unadjusted median and interquartile range values of hemostatic factors by estrogen type and MPA use
Hemostatic parameter
Hormone therapy
CEE alone (n ¼ 71) CEE + MPA (n ¼ 45) EE alone (n ¼ 45) EE + MPA (n ¼ 47)
ETP-nAPCsr 0.86 (0.26–1.44) 0.81 (0.51–1.65) 0.49 (0.27–1.18) 0.36 (0.21–0.83)
FVII activity (%) 140 (127–167) 125 (102–148) 126 (118–151) 122 (110–136)
D-dimer (ng mL)1) 474 (362–664) 524 (367–788) 509 (390–724) 414 (289–679)
AT activity (%) 104 (99–110) 103 (98–108) 107 (99–115) 108 (100–115)
Free protein S (%) 89 (76–99) 88 (74–102) 90 (77–102) 98 (77–116)
Total protein S (%) 110 (100–120) 100 (93–117) 112 (102–120) 117 (102–128)
AT, antithrombin; CEE, conjugated equine estrogen; EE, esterified estrogen; ETP-nAPCsr, endogenous thrombin potential normalized activated
protein C sensitivity ratio; FVIII, factor VIII; MPA, medroxyprogesterone.
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mutation (P ¼ 0.652). Among the 175 women without the
FVL mutation, median nAPCsr measures for low, modal, and
high CEE doses were 0.69, 0.76, 0.74, respectively, and were
0.42, 0.42, 1.06 for EE doses, respectively. Eighty per cent of
women were using a modal dose (Table 1). Among the 151
womenwithout the FVLmutation and using themodal dose of
estrogen (0.625 mg), we again found that CEE users were more
resistant to APC than EE users (ratio: 1.57; 95%CI: 1.04–2.36;
P ¼ 0.030). When data were stratified by MPA use among
women without the FVL mutation, CEE users remained more
resistant to APC than EE users both among women not using
MPA (ratio: 1.22; 95% CI: 0.69–2.26; P ¼ 0.495) and among
women using MPA (ratio: 2.15; 95% CI: 1.35–3.42; P ¼
0.002). Although the point estimate was larger among MPA
users, there was no statistical evidence of an interaction
between estrogen type and MPA use (P ¼ 0.212). Recency of
starting either EE or CEE (< 2 year vs. > 2 years) was not
associated with APC resistance and there was no suggestion of
an interaction between estrogen type and recency (P ¼ 0.908).
The median daily dose of prescribed MPA was 2.5 mg: 4%
of women were using lower doses and 25% were using higher
doses. The use of MPA was not associated with increased
resistance to APC among CEE users (MPA:no-MPA ratio:
1.36; 95% CI: 0.83–2.23; P ¼ 0.220) nor among EE users
(ratio: 0.90; 95% CI: 0.52–1.55; P ¼ 0.689) after adjusting for
age, body mass index, and race. The use of MPA was
associated with lower FVII levels in both CEE (ratio: 0.91;
95% CI: 0.82–1.00; P ¼ 0.047) and EE (ratio: 0.85; 95% CI:
0.85–0.93;P ¼ 0.001) users. For the remaining four hemostatic
measures, no clear or consistent differences were found.
Discussion
Previously, we reported that CEE use in postmenopausal
women was associated with an increased risk of venous
thrombosis compared with EE use [4]. To support this finding,
we have investigated the hemostatic profile in healthy users of
both types of hormones and found that CEE users were more
resistant to APC and had a more prothrombotic hemostatic
profile than EE users. Restricting analyses to women using only
modal doses of CEE and EE did not change the interpretation
nor did stratification by MPA use. We also found that CEE
users generally had lower AT and total and free protein S levels
and higher FVII levels than EE users and these findings are
similar to published observations of APC resistance phenotype
[10]. We also had reported that MPA use was associated with
an increased risk of venous thrombosis but we did not find that
MPA use was associated with a more prothrombotic hemo-
static profile than non-use of MPA.
Several limitations should be considered. The use of
hormone therapy was not randomly assigned. Women and
their physicians chose whether to use hormones according to
clinical indication, which could induce confounding. The type
of estrogen received, however, was dictated primarily by
changes over time in the GHC formulary and not by patient or
physician choice. Although we adjusted for patient character-
istics that may be associated with hemostatic parameter levels
and hormone use, residual confounding by these or other
unmeasured characteristics may be present.
Equivalence of estrogen exposure relied exclusively on daily
dosing and not on a standard of bioequivalence of the
estrogenic compounds in CEE and EE. Conjugated equine
estrogens contain 10 known biologically active estrogen
compounds as well as others that are not characterized
[20,21]. The primary estrogen compounds in CEE are estrone
sulfate, constituting53%of the estrogens, and equilin sulfate,
constituting about 25% of the product [21,22]. Esterified
estrogens contain 80% estrone sulfate and 11% equilin
sulfate [22]. There is a large literature demonstrating pro-
thrombotic characteristics of oral CEE and estradiol estrogen
use [11,12,23–30], but a comparable literature for EE use does
not exist. The mechanism by which some estrogens increase
thrombotic risk is not known. Our data do not suggest a strong
role for protein S, AT, or FVII as estrogen-type differences
were generally not strong, although some were statistically
significant. It has been hypothesized that tissue factor pathway
inhibitor and its influence on activated FX levels may underlie
estrogen’s role in modulating nAPCsr levels [31]. Estrogen has
been shown to decrease levels of glucosylceramide, which
serves as a co-factor for APC [32].
The prothrombotic characteristics of MPA are not known.
The lack of an association between MPA use and APC
resistance suggests that if MPA is associated with increased
thrombotic risk, as was observed in clinical trials [2,3], it may
Table 3 Unadjusted median hemostatic factor values by estrogen type and adjusted ratios
Hemostatic parameter
Estrogen type comparisons
CEE median (IQ range)
(n ¼ 116)
EE median (IQ range)
(n ¼ 92)
Adjusted* CEE:EE ratio (95% CI),
P-value
ETP-nAPCsr 0.85 (0.37–1.54) 0.46 (0.21–1.07) 1.52 (1.07–2.17), 0.020
FVII activity (%) 137 (116–160) 124 (116–146) 1.07 (0.99–1.14), 0.073
D-dimer (ng mL)1) 490 (362–683) 473 (346–698) 1.01 (0.89–1.14), 0.856
AT activity (%) 103 (98–110) 107 (100–115) 0.97 (0.94–1.00), 0.027
Free protein S (%) 89 (74–101) 91 (77–109) 0.95 (0.90–1.01), 0.115
Total protein S (%) 107 (97–118) 113 (102–125) 0.95 (0.91–0.99), 0.008
AT, antithrombin; CEE, conjugated equine estrogen; CI, confidence interval; EE, esterified estrogen; ETP-nAPCsr, endogenous thrombin potential
normalized activated protein C sensitivity ratio; FVIII, factor VIII; IQ, interquartile; MPA, medroxyprogesterone. *Adjusted for age, race, and
body mass index.
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operate through a different biologic pathway. The MPA
comparison, however, is nearly completely confounded by
hysterectomy status, which limits the interpretation of these
findings. Comparison of MPA use with other progestin types
among women with an intact uterus would be a clinically more
informative investigation.
Menopausal women continue to use hormones to treat
vasomotor symptoms, andvenous thrombosis remains themost
serious side effect associated with short-term use. Our data
demonstrate that CEE use was associated with higher levels of
APC resistancewhen comparedwithEEuse inpostmenopausal
women. These findings need to be replicated in a clinical trial of
women seeking medicinal relief from vasomotor symptoms
related to menopause to understand better the relative safety
and effectiveness of these drugs. If replicated, they may have
health-related implications for women and their physicians
when choosing an estrogen for symptom relief.
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